Startseite Kongressberichte & Archiv 2021 ASCO Annual Meeting Head & Neck Cancer Head and Neck Cancer
Head and Neck Cancer
Camrelizumab versus placebo combined with gemcitabine and cisplatin for recurrent or metastatic nasopharyngeal carcinoma: A randomized, double-blind, phase 3 trial.
Li Zhang, Yunpeng Yang, Song Qu, et al.
The study authors suggest that with the addition of camrelizumab to gemcitabine and cisplatin (GP) there could be a standard of care for recurrent or metastatic nasopharyngeal carcinoma. This treatment significantly prolonged PFS as first-line therapy with a manageable safety profile. Clinical trial information: NCT03707509
Cabozantinib versus placebo in patients with radioiodine-refractory differentiated thyroid cancer who have progressed after prior VEGFR-targeted therapy: Results from the phase 3 COSMIC-311 trial.
Marcia S. Brose, Bruce Robinson, Steven I. Sherman, et al.
The study authors showed, that in patients with radioiodine (RAI)-refractory differentiated thyroid cancer (DTC) after prior VEGFR-targeted therapy Cabozantinib had a clinically and statistically significant improvement in progression-free survival over placebo. There were no unexpected toxicities. The authors suggest Cabozantinib as a new standard of care in patients with previously treated DTC. Clinical trial information: NCT03690388
A phase II trial cohort of nivolumab plus ipilimumab in patients (Pts) with recurrent/metastatic salivary gland cancers (R/M SGCs).
Bharat Burman, Eric Jeffrey Sherman, Lara Dunn, et al.
The study authors conclude, that the cohort met its primary endpoint. The responses were dramatic and durable. Clinical trial information: NCT03172624
Metronomic capecitabine as adjuvant therapy in locoregionally advanced nasopharyngeal carcinoma: A phase 3, multicenter, randomized controlled trial.
Jun Ma, Yu-Pei Chen, Ying Sun, et al.
The study authors show, that the adjuvant addition of metronomic capecitabine to chemoradiotherapy significantly improved relapse-free survival in locoregionally advanced nasopharyngeal carcinoma. The safety profile was manageable without compromising the quality of life. Clinical trial information: NCT02958111
Adjuvant capecitabine in locoregionally advanced nasopharyngeal carcinoma: A multicenter randomized controlled phase III trial.
Jingjing Miao, Lin Wang, Sze Huey Tan, et al.
The study authors conclude, that in high-risk locoregionally advanced nasopharyngeal carcinoma the addition of capecitabine to concurrent cisplatin and radiotherapy (CCRT) allowed a better disease control than CCRT alone. Clinical trial information: NCT02143388
Association of pathological response to neoadjuvant pembrolizumab with tumor PD-L1 expression and high disease-free survival (DFS) in patients with resectable, local-regionally advanced, head and neck squamous cell carcinoma (HNSCC).
Trisha Michel Wise-Draper, Vinita Takiar, Michelle Lynn Mierzwa, et al.
The study authors conclude, that pathological response to neoadjuvant pembrolizumab is associated with PD-L1 CPS≥1 and high disease-free survival in patients with resectable, local-regionally advanced, HNSCC. Clinical trial information: NCT02641093
Primary results of the phase II CheckRad-CD8 trial: First-line treatment of locally advanced head and neck squamous cell carcinoma (HNSCC) with double checkpoint blockade and radiotherapy dependent on intratumoral CD8+ T-cell infiltration.
Markus Hecht, Markus Eckstein, Sandra Rutzner, et al.
The study authors conclude, that the trial primary endpoint feasibility was met. It was shown, that after induction therapy CD8+ T cell-based pathological patient selection identifies patients with promising progression-free survival rates after chemotherapy-free radio-immunotherapy. Clinical trial information: nct03426657
Enhanced pathologic tumor response with two cycles of neoadjuvant pembrolizumab in surgically resectable, locally advanced HPV-negative head and neck squamous cell carcinoma (HNSCC).
Ravindra Uppaluri, Rebecca Chernock, Mena Mansour, et al.
The study authors conclude, that two (vs one) cycles of neoadjuvant pembrolizumab resulted in a two-fold increase in the frequency of pTR-2 (44% vs 22%). This implies that by increasing the number of cycles and the treatment interval the frequency of pathologic tumor response to neoadjuvant pembrolizumab can be improved. Clinical trial information: NCT02296684